news‘Revolutionary’ liquid sickle cell treatment has been unveiled28 October 2019 | By Rachael Harper (European Pharmaceutical Review)A new liquid formulation of hydroxycarbamide to treat sickle cell disease will “enable doctors to personalise doses in children".
newsNova Laboratories secures FDA approval for Xaluprine1 May 2014 | By Nova LaboratoriesUK pharmaceutical firm Nova Laboratories has secured U.S Food and Drug Administration approval for its acute lymphoblastic leukaemia (ALL) product Xaluprine...
newsNova Laboratories announces FDA filing of New Drug Application for the treatment of childhood acute lymphoblastic leukemia4 December 2013 | By Nova LaboratoriesThe product has been granted orphan drug designation by the FDA, a status given to a product intended for the treatment of a rare disease or condition...